Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a note issued to investors on Tuesday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

EGRX opened at $0.50 on Tuesday. The company’s 50 day moving average is $2.59 and its 200-day moving average is $3.89. Eagle Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $14.40.

Hedge Funds Weigh In On Eagle Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Headlands Technologies LLC grew its holdings in shares of Eagle Pharmaceuticals by 75.7% during the first quarter. Headlands Technologies LLC now owns 6,641 shares of the specialty pharmaceutical company’s stock worth $35,000 after purchasing an additional 2,861 shares during the last quarter. Mackenzie Financial Corp bought a new stake in Eagle Pharmaceuticals during the 2nd quarter worth approximately $60,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Eagle Pharmaceuticals in the 2nd quarter valued at approximately $65,000. Fidelis Capital Partners LLC acquired a new position in Eagle Pharmaceuticals in the 2nd quarter valued at approximately $71,000. Finally, Vanguard Personalized Indexing Management LLC bought a new position in shares of Eagle Pharmaceuticals during the second quarter valued at $76,000. Institutional investors and hedge funds own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.